Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers

NCT03413982 | Recruiting

• 1 other identifier: STUDY00141546
• Study Type: observational
• Target: 1,000
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to create a registry, which is a "bank" of information about patients who have had similar medical conditions and treatments. The registry will be used by researchers to learn more about long term outcome of patients with bladder cancer, how bladder cancer tissues are related to tumor development, recurrence and survival.

Conditions

Bladder Cancer

Outcome Measures

Primary Outcomes (1)

• Blood, urine and tissue characteristics of bladder cancer patients

  Samples will be collected over a 24 month period for patients to build a biorepository for future research on how they are related to tumor development, recurrence and survival.

  24 months

Study Arms (1)

BC Patients

Patients with bladder cancer. This registry involves no intervention. Blood, urine, and tissue samples will be collected to be used for research.

Other: Registry

Interventions

Registry OTHER

Patient registry

BC Patients

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients who are receiving care from KUMC clinics will be considered for this registry.

You may qualify if:

• Patients who present to clinic with presumed bladder cancer or have a diagnosis of bladder cancer are eligible to participate
• Patients can participate in any additional research studies during the patients' participation within this protocol.

You may not qualify if:

• Patients who do not have presumed bladder cancer will not be eligible

Sponsors & Collaborators

• University of Kansas Medical Center: lead

Study Sites (1)

University of Kansas Medical Center

Kansas City, Kansas, 66160, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood, urine, and tissue are being collected.

MeSH Terms

Conditions

Urinary Bladder Neoplasms

Interventions

Registries

Condition Hierarchy (Ancestors)

Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Urinary Bladder Diseases; Urologic Diseases; Male Urogenital Diseases

Intervention Hierarchy (Ancestors)

Data Collection; Epidemiologic Methods; Investigative Techniques; Records; Organization and Administration; Health Services Administration; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Officials

• John Taylor, MD

  University of Kansas Medical Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jane Ladesma

CONTACT

913-588-8721; jledesma2@kumc.edu

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 24 Months
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 10, 2018
• First Posted: January 29, 2018
• Study Start: November 2, 2017
• Primary Completion (Estimated): January 1, 2035
• Study Completion (Estimated): January 1, 2035
• Last Updated: March 10, 2026

Record last verified: 2026-03

Locations

US (1)